A pharmacy benefit manager may not pay a pharmacy a different amount for a drug on the ground that it is a 340B drug or the pharmacy is a 340B entity. It may not charge a 340B entity fees, restrict its network access, add patient charges or extra requirements for taking part in 340B, or require a 340B modifier on a claim.
Bill
SB 138
Act
Laws of Utah 2020, ch. 275
Session
2020
Signed
28 March 2020
In effect
12 May 2020
Applies to
Pharmacy benefit managers
Limits
Applies to contracts entered into or renewed on or after January 1, 2021. The payment and modifier rules do not cover drugs paid for by Medicaid.
require a claim for a drug to include a modifier to indicate that the drug is a 340B drug unless the claim is for payment, directly or indirectly, by the Medicaid program
An insurer may not pay a federally qualified health center, or a pharmacy it runs or contracts with, a different amount for a drug on the ground of 340B status, and may not charge it fees, limit its network access or add patient charges or other requirements for taking part in 340B. An insurer may not require a 340B modifier on a claim.
Bill
SB 140
Act
Laws of Utah 2021, ch. 317
Session
2021
Signed
17 March 2021
In effect
5 May 2021
Applies to
Health insurers
Limits
Covers federally qualified health centers and their pharmacies only. Applies to contracts entered into or renewed on or after January 1, 2022. The payment and modifier rules do not cover drugs paid for by Medicaid.
require a claim for a drug to include a modifier to indicate that the drug is a 340B drug unless the claim is for payment
A manufacturer may not stop a pharmacy and a 340B entity from contracting, deny them a drug, block a 340B drug reaching a location the entity authorizes, limit the time to restock or to claim 340B pricing, or demand claim or utilization data as a condition of supply.
Bill
SB 69
Session
2025
In effect
7 May 2025
Applies to
Drug manufacturers, their agents and affiliates
Limits
Data that federal law requires is allowed, and delivery that federal law prohibits is not required. The state employee benefit program may adjust its practices to offset any cost.
the acquisition, dispensing, or delivery of a 340B drug to any location authorized by a 340B entity to receive the drug, unless prohibited by federal law
Rewrites the section added in 2025: a manufacturer may not stop a pharmacy or 340B covered entity from contracting, limit 340B drugs reaching authorized locations, set time limits on restocking or claims, force a choice of supplier, demand claim or contract data as a condition, or interfere with pharmacy contracts.
Bill
HB 356
Session
2026
In effect
6 May 2026
Applies to
Drug manufacturers, their agents and affiliates
Limits
Amends the section added by the 2025 act, which is listed.
A manufacturer may not: (a) directly or indirectly restrict or prohibit: (i) a pharmacy from contracting with a 340B covered entity, including by denying the pharmacy access to a drug that is manufactured by the manufacturer
Plain-language summaries, not legal advice. Laws change, and court rulings on them are not covered here. Read the state’s own page before you rely on one.